Alumis stock is trading higher on Tuesday after the company announced it entered into a collaboration and licensing agreement with Kaken Pharmaceuticals.
Shares of Alumis (NASDAQ:ALMS) traded ~14% higher in the premarket on Tuesday after the California-based biopharma announced ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results